372 Index Name Paper ref. Name Paper ref. Tejerina, T Wed 228, Wed 215, Mon 206 Tejerina, Teresa Thu 264, Tue 144 Tekes, K Wed 050 Tékus, V Tue 078 Teleshova, E Tue 024 Tenayuca, J Tue 378 Teng, B Thu 057 Teng, S-F Wed 035 Tengrungsun, T Thu 443 Teraoka, K Wed 278 Teräs, M Mon 256 Ternant, D Tue 198 Ternant, T Mon 363 Terrón, JA Thu 265 Terry, D FC02.1.2 Terzian, A FC17.5.5 Tesfaye, H Tue 137, Tue 445 Tesmer, J Thu 075 Tesse, A Wed 216, Wed 196 Teulon, I Mon 363 Teyssier, C FC18.3.5 Tezcan, K Mon 418 Tfayli, A FC01.3.4 Tfelt-Hansen, J FC15.2.3 Thacker, T FC11.3.2 Þahin, S Tue 030 Thakore, P Wed 260 Thakur, S Thu 290 Thal, D Thu 075 Thampithak, A Tue 277, Thu 305 Thangboonjit, W Mon 357 Thapa, KK Tue 097, Tue 120 Theron, A Thu 012 Thiblin, I FC14.5.2 Thiele, Sie FC11.5.5 Thiemermann, C FC18.3.6 Thompson, J FC17.1.3 Thompson, MA FC04.2.5 Thomsen, A Tue 358 Thomsen, H Wed 161, Mon 360 Thomsen, M Tue 065 Thomson, M Tue 093 Thor, D Thu 087 Thorneloe, KS W03.5 Thörngren, J-O FC14.1.6 Thorsen, TS YI.10 Thürmann, PA W35.1, Tue 313, Wed 119, Tue 131, Tue 314, Tue 108 Thuillez, C Wed 207, Thu 242 Tian, W-W Thu 210 Tian, Y-L Thu 277 Tian, Y-P Mon 265 Tibboel, D FC10.4.1 Tiburcio, R Tue 420 Tie, Lu Thu 076 Tikka, S Thu 052, Thu 071 Tikoo, K Mon 171 Tilley, S Thu 057 Tilton, R FC16.5.3 Timar, J Wed 185 Timar, J Thu 192 Timotijevic, G FC16.3.6 Tinel, H Thu 091 Tirkkonen, T Mon 144 Tirona, R Tue 054, Mon 072, Tue 301, FC02.1.6 Tirotta, E FC17.4.6 Tiwari, V Mon 183 Tiziana, B Thu 400 Tjønneland, A Tue 482 Tkeba, Y Tue 336 Tlala, V Tue 110 Tlaskalova-Hogenova, H Wed 118 Tobaiqy, M Tue 109 Toda, N Wed 200 Toda, T Mon 177, Mon 182, Tue 318, Tue 138 Todoroki, M Mon 272 Todorovic, S FC03.2.2 Todorovic, Z Tue 098, Tue 013, Tue 026, Wed 135, Wed 134 W34.1, W34.2 Todt, H Mon 218, Mon 217 Toft, E Tue 303 Tognolini, M Tue 258, Mon 381 Tohamy, MA Mon 340 Toklu, HZ Tue 027 Tokuoka, S Tue 373 Tölle, TR W03.6 Tolonen, A Thu 348 Tolstanova, G W02.2.7 Tomalik-Scharte, D Mon 384, Thu 010 Tomic, S Mon 342, Mon 343, Mon 370, Wed 112, Tue 121 Tomic, Z W34.4 Tomita, K FC09.1.6 Tomita, S Mon 180, Wed 247 Tomlinson, B Tue 139, FC02.4.6, Tue 140 Tomlinson, G FC10.5.3 Tomono, Y Mon 035 Tomos, C Tue 126, Thu 206 Tomsig, J Wed 076 Tong, J Mon 468, Mon 414, Tue 412, Mon 408 Tong, X Tue 028 Tonkin, J Mon 102 Tontonoz, P FC18.1.1 Tontson, L Thu 077 Topal Tanyilmaz, G Thu 266 Topcu, I Mon 117 Torii, K W02.1.7 Torndal, U-B Tue 383 Törnquist, K Thu 079 Torp-Pedersen, C FC13.3.6, FC04.2.4, Mon 119, Mon 118 Torrens, M Thu 177 Torres Domínguez, A Thu 358 Torres, A Wed 131 Torres, I Wed 177 Toste, F Tue 162 Tostes, R FC06.1.5 Tóth, A Tue 125 Toth, D Mon 283 Tóth, DM Mon 401 Toufiño, C Wed 209 Toukola, L W21.4 Tourette, A Mon 084 Touw, DJ W28.5, W29.4
Name Paper ref. Name Paper ref. Touyz, R W04.3.1 Tovey, MG FC09.2.3 Toyama, MH Thu 374, Wed 297 Toylu, A Tue 200 Toyohira, Y Tue 072 Tozawa, A Mon 435 Trabelsi, S FC07.3.6, Mon 020, Mon 021 Trajano, ETL Wed 342 Tran, K Tue 309 Trandafilovic, M Thu 359 Trandafirescu, C Tue 102 Tran-Van-Minh, A FC03.2.4 Trapasso, E Thu 316, Thu 364 Travassos, AS Thu 193 Traynelis, SF Wed 084 Treede, R-D W03.6 Treinys, R Thu 023 Trejo, E Wed 040 Trenti, A Thu 360 Trevisani, M W03.1 Trevisi, L Thu 360 Tributino, J Mon 398 Tricoire, J Mon 145, Mon 132 Trifa, A Mon 417, Mon 438, Tue 481 Trifirò, G FC04.1.6, FC04.4.5, FC04.4.6 Tringham, E FC03.2.1 Trinh, S Wed 306 Trinquet, E Thu 035, FC11.2.1, Wed 077, FC11.3.5 Tripatara, P Thu 361 Trujillo-Ferrara, JG Tue 195 Truter, I Mon 026 Truter, Ilse Tue 110, Tue 111, Tue 112 Tsai, H-Y Wed 328 Tsai, M-H Wed 430 Tsakiris, S Thu 431 Tue 381 Tsang, LL Thu 341 Tsartsalis, S Tue 141, Mon 297, Tue 126 Tschische, P Thu 078 Tse, HF Tue 346, Thu 270 Tseng, C-J Tue 146 Tseng, T-L Thu 362 Tsirlis, AT Mon 297 Tsiwtsiwadze, ET Mon 192 Tso, AWK Mon 271, Mon 159 Tsoli, M W06.3 Tsopanoglou, N Thu 095 Tsuboi, A Wed 372 Tsuchida, K Tue 236 Tsuchiya, H Wed 189 Tsuchiya, K Mon 180 Tsuda, S Tue 132 Tsuji, F Mon 402, Mon 112 Tsuji, M Thu 422, Thu 397, Wed 128, Tue 443, Thu 423 Tsujimoto, G Wed 064 Tsukada, H Tue 217 Tsukahara, F Thu 444 Tsukahara, Y Mon 112 Tsukuda, K Mon 439 Tsuruhisa, M Wed 223 Tsuruma, K Thu 220 Tsuruta, H Tue 474 Tsuruta, T Tue 311 Tsushima, H Tue 147 Tsutsui, M Tue 072, Thu 344 Tsutsui, S Tue 085 Tu, S Wed 366 Tubéry, M FC04.3.5 Tuleu, C FC10.3.4 Tulunay, FC Tue 142 Tumanovskaya, L FC06.1.6 Tunaru, S Wed 056 Tuncer, M Mon 419, Wed 253 Tuncok, Y Tue 449, Tue 366, Mon 474 Tunkova, A Mon 081, Wed 118 Tunthong, R Tue 127 Tuominen, RK Tue 433, FC09.5.4, Mon 341 Turcekova, K Mon 219 Turecek, R Thu 028 Turgeon, J Tue 051 Turkanovic, J Tue 066 Turkoviæ, B W02.3.1 Turpeinen, AM Wed 361 Turpeinen, T FC09.1.5, Tue 278 Tursas, L Thu 348 Turunen, P Thu 051 Tvete, IF Tue 143 Tyner, S Tue 090 Uchida, N Tue 320 Uchida, S Tue 144 Uchimura, T Thu 331 Uchipichat, V Wed 124 Uckert, S FC08.3.5 Udoh, F Thu 332 Ückert, S Tue 212, Tue 211, Tue 210 Ueda, M Wed 414 Ueda, Y Tue 163 Uematsu, S Mon 313 Uemura, T Thu 034 Ueno, S Tue 072 Uezono, Y Wed 065 Ugur, Ö Thu 049 Uhl, G Thu 176 Uhlen, S Mon 397, Wed 069 Uhlhaas, P FC17.2.2 Uhlik, J Tue 445 Ulak, G Thu 401, Wed 351 Ulbrich, C Thu 267, Wed 252 Ulsund, AH Wed 026 Ulugol, A Mon 098 Ulukus, C Tue 411 Uluoglu, C Tue 029 Ulupinar, E Wed 406 Ulusoy, HB Tue 030, Tue 031 Ulzurrun, E Wed 109 Uma, S Thu 229, Thu 230 Umegaki, K Tue 067 Umemura, K W23.4, Tue 473 Undale, V Mon 336 Undale, VR Thu 363 Ungvári, E Mon 150 Uotani, T W23.4, Tue 473 Upasani, CD Thu 363 Uranga Piña, R Wed 311 Uras, R Tue 133 Urban, N FC17.1.3 Index 373
- Page 1:
of basic and clinical pharmacology
- Page 4 and 5:
Congress patron 2 HRH Crown Princes
- Page 6 and 7:
Congress President Kim Brøsen Secr
- Page 8 and 9:
General information Registration &
- Page 10 and 11:
Banks, currency & credit cards The
- Page 12 and 13:
Information to presenters ■ The a
- Page 14 and 15:
Hotel Bella Center Copenhagen Groun
- Page 16 and 17:
Programme at a glance Time Hall A2
- Page 18 and 19:
16 General events General events Op
- Page 20 and 21:
Programme outline Plenary lectures
- Page 22 and 23:
FC10 Drugs for half the world: Paed
- Page 24 and 25:
Tue 12:45 W13 Workshop: Novel perip
- Page 26 and 27:
W01 Pharmacology of adrenoceptors:
- Page 28 and 29:
W02 Symposium on advances in GI pha
- Page 30 and 31:
W04 Symposium: Antioxidants as ther
- Page 32 and 33:
Plenary lectures PL01 Plenary lectu
- Page 34 and 35:
FC02 Transmembrane transport: Persp
- Page 36 and 37:
FC04 Pharmacoepidemiology, current
- Page 38 and 39:
FC06 The heart gone wrong: Stabiliz
- Page 40 and 41:
FC09 Inflammation and immunopharmac
- Page 42 and 43:
W02 Symposium on advances in GI pha
- Page 44 and 45:
SS01 Sponsored symposium Sponsored
- Page 46 and 47:
W06 Workshop. Effect of disease on
- Page 48 and 49:
W08 Workshop. Identifying targets f
- Page 50 and 51:
W10 Workshop. Innovative Medicines
- Page 52 and 53:
FC01 Clinical pharmacology in the e
- Page 54 and 55:
FC03 Ion channels in analgesia and
- Page 56 and 57:
FC05 Translational science in the m
- Page 58 and 59:
FC06 The heart gone wrong: Stabiliz
- Page 60 and 61:
FC08 Development in the treatment o
- Page 62 and 63:
Plenary lectures PL04 Plenary lectu
- Page 64 and 65:
FC01 Clinical pharmacology in the e
- Page 66 and 67:
FC03 Ion channels in analgesia and
- Page 68 and 69:
FC05 Translational science in the m
- Page 70 and 71:
FC07 Simulation and data modelling
- Page 72 and 73:
FC09 Inflammation and immunopharmac
- Page 74 and 75:
W12 Workshop. Experimental pain met
- Page 76 and 77:
W14 Workshop. Translating the human
- Page 78 and 79:
W15 Workshop. The IUPHAR initiative
- Page 80 and 81:
W17 Workshop. Standards for PhD Edu
- Page 82 and 83:
W19 Workshop. Influence of degenera
- Page 84 and 85:
FC02 Transmembrane transport: Persp
- Page 86 and 87:
FC04 Pharmacoepidemiology, current
- Page 88 and 89:
FC06 The heart gone wrong: Stabiliz
- Page 90 and 91:
FC08 Development in the treatment o
- Page 92 and 93:
PL10 ASPET Plenary Lecture Chair: T
- Page 94 and 95:
FC10 Drugs for half the world: Paed
- Page 96 and 97:
FC12 Ion channelopathies: New windo
- Page 98 and 99:
FC14 Addiction and doping: Neurobio
- Page 100 and 101:
FC17 New approaches and targets in
- Page 102 and 103:
W04 Symposium: Antioxidants as ther
- Page 104 and 105:
W21 Workshop. Inflammation - here,
- Page 106 and 107:
W23 Workshop. Applying pharmacogeno
- Page 108 and 109:
W25 Workshop. High science in the l
- Page 110 and 111:
W27 Workshop. Approaches to medicin
- Page 112 and 113:
FC11 G protein-coupled 7TM receptor
- Page 114 and 115:
FC13 Maximising benefits and minimi
- Page 116 and 117:
FC15 Endothelium in Health and dise
- Page 118 and 119:
FC17 New approaches and targets in
- Page 120 and 121:
FC18 Nuclear receptor targets for t
- Page 122 and 123:
PL16 Plenary Lecture Supported by a
- Page 124 and 125:
FC11 G protein-coupled 7TM receptor
- Page 126 and 127:
FC13 Maximising benefits and minimi
- Page 128 and 129:
FC15 Endothelium in Health and dise
- Page 130 and 131:
FC17 New approaches and targets in
- Page 132 and 133:
W28 Workshop. The Boehringer-Ingelh
- Page 134 and 135:
W30 Workshop. Is eNOS still a valid
- Page 136 and 137:
W32 Workshop. The good, the bad and
- Page 138 and 139:
W34 Workshop. State-of-the-art of b
- Page 140 and 141:
FC10 Drugs for half the world: Pedi
- Page 142 and 143:
FC12 Ion channelopathies: New windo
- Page 144 and 145:
FC14 Addiction and doping: Neurobio
- Page 146 and 147:
FC16 Natural products: Past and fut
- Page 148 and 149:
FC18 Nuclear receptor targets for t
- Page 150 and 151:
PL22 Plenary Lecture Chair: Zhi-Bin
- Page 152 and 153:
FC11 G protein-coupled 7TM receptor
- Page 154 and 155:
FC13 Maximising benefits and minimi
- Page 156 and 157:
FC15 Endothelium in health and dise
- Page 158 and 159:
FC17 New approaches and targets in
- Page 160 and 161:
158
- Page 162 and 163:
FC01 Clinical pharmacology in the e
- Page 164 and 165:
FC01 Clinical pharmacology in the e
- Page 166 and 167:
FC02 Transmembrane transport: Persp
- Page 168 and 169:
FC03 Ion channels in analgesia and
- Page 170 and 171:
W12 Experimental pain methods in de
- Page 172 and 173:
FC04 Pharmacoepidemiology, current
- Page 174 and 175:
FC05 Translational science in the m
- Page 176 and 177:
FC05 Translational science in the m
- Page 178 and 179:
FC06 The heart gone wrong; stabiliz
- Page 180 and 181:
FC07 Simulation and data modelling
- Page 182 and 183:
FC08 Developments in the treatment
- Page 184 and 185:
FC09 Inflammation and immunopharmac
- Page 186 and 187:
FC09 Inflammation and immunopharmac
- Page 188 and 189:
FC09 Inflammation and immunopharmac
- Page 190 and 191:
FC13 Maximising benefits and minimi
- Page 192 and 193:
FC13 Maximising benefits and minimi
- Page 194 and 195:
W03 Targeting TRP channels for pain
- Page 196 and 197:
W19 Influence of degeneration and r
- Page 198 and 199:
W19 Influence of degeneration and r
- Page 200 and 201:
W20 Pharmacology education for a su
- Page 202 and 203:
FC01 Clinical pharmacology in the e
- Page 204 and 205:
FC02 Transmembrane transport: Persp
- Page 206 and 207:
FC02 Transmembrane transport: Persp
- Page 208 and 209:
FC04 Pharmacoepidemiology, current
- Page 210 and 211:
FC05 Translational science in the m
- Page 212 and 213:
FC05 Translational science in the m
- Page 214 and 215:
FC06 The heart gone wrong; stabiliz
- Page 216 and 217:
FC07 Simulation and data modelling
- Page 218 and 219:
FC08 Developments in the treatment
- Page 220 and 221:
FC09 Inflammation and immunopharmac
- Page 222 and 223:
FC09 Inflammation and immunopharmac
- Page 224 and 225:
FC09 Inflammation and immunopharmac
- Page 226 and 227:
FC13 Maximising benefits and minimi
- Page 228 and 229:
FC13 Maximising benefits and minimi
- Page 230 and 231:
FC19 General session Tue 361 Analge
- Page 232 and 233:
FC19 General session - Biologics Tu
- Page 234 and 235:
FC19 General session - Haematology
- Page 236 and 237:
FC19 General session - oncology Tue
- Page 238 and 239:
FC19 General session - oncology Tue
- Page 240 and 241:
FC19 General session - Toxicology T
- Page 242 and 243:
W02 Symposium on advances in GI pha
- Page 244 and 245:
W11 New opportunities in the pharma
- Page 246 and 247:
W23 Applying pharmacogenomics (PGX)
- Page 248 and 249:
FC10 Drugs for half the world: Paed
- Page 250 and 251:
FC11 G protein-coupled 7TM receptor
- Page 252 and 253:
FC11 G protein-coupled 7TM receptor
- Page 254 and 255:
FC12 Ion channelopathies: New windo
- Page 256 and 257:
FC13 Maximising benefits and minimi
- Page 258 and 259:
FC13 Maximising benefits and minimi
- Page 260 and 261:
FC14 Addiction and doping: Neurobio
- Page 262 and 263:
FC15 Endothelium in health and dise
- Page 264 and 265:
FC15 Endothelium in health and dise
- Page 266 and 267:
FC15 Endothelium in health and dise
- Page 268 and 269:
W30 Is eNOS Still a valid therapeut
- Page 270 and 271:
FC16 Natural products: Past and fut
- Page 272 and 273:
FC16 Natural products: Past and fut
- Page 274 and 275:
FC16 Natural products: Past and fut
- Page 276 and 277:
FC17 New approaches and targets in
- Page 278 and 279:
FC17 New approaches and targets in
- Page 280 and 281:
W34 State-of-the-art of basic and c
- Page 282 and 283:
FC10 Drugs for half the world: Paed
- Page 284 and 285:
FC11 G protein-coupled 7TM receptor
- Page 286 and 287:
FC11 G protein-coupled 7TM receptor
- Page 288 and 289:
FC11 G protein-coupled 7TM receptor
- Page 290 and 291:
FC13 Maximising benefits and minimi
- Page 292 and 293:
FC13 Maximising benefits and minimi
- Page 294 and 295:
W29 New horizons in therapeutic dru
- Page 296 and 297:
FC14 Addiction and doping: Neurobio
- Page 298 and 299:
FC15 Endothelium in health and dise
- Page 300 and 301:
FC15 Endothelium in health and dise
- Page 302 and 303:
FC15 Endothelium in health and dise
- Page 304 and 305:
FC16 Natural products: Past and fut
- Page 306 and 307:
FC16 Natural products: Past and fut
- Page 308 and 309:
FC16 Natural products: Past and fut
- Page 310 and 311:
FC16 Natural products: Past and fut
- Page 312 and 313:
FC17 New approaches and targets in
- Page 314 and 315:
FC18 Nuclear receptor targets for t
- Page 316 and 317:
314 Index Name Paper ref. Name Pape
- Page 318 and 319:
316 Index Name Paper ref. Name Pape
- Page 320 and 321:
318 Index Name Paper ref. Name Pape
- Page 322 and 323:
320 Index Name Paper ref. Name Pape
- Page 324 and 325: 322 Index Name Paper ref. Name Pape
- Page 326 and 327: 324 Index Name Paper ref. Name Pape
- Page 328 and 329: 326 Index Name Paper ref. Name Pape
- Page 330 and 331: 328 Index Name Paper ref. Name Pape
- Page 332 and 333: 330 Index Name Paper ref. Name Pape
- Page 334 and 335: 332 Index Name Paper ref. Name Pape
- Page 336 and 337: 334 Index Name Paper ref. Name Pape
- Page 338 and 339: 336 Index Name Paper ref. Name Pape
- Page 340 and 341: 338 Index Name Paper ref. Name Pape
- Page 342 and 343: 340 Index Name Paper ref. Name Pape
- Page 344 and 345: 342 Index Name Paper ref. Name Pape
- Page 346 and 347: 344 Index Name Paper ref. Name Pape
- Page 348 and 349: 346 Index Name Paper ref. Name Pape
- Page 350 and 351: 348 Index Name Paper ref. Name Pape
- Page 352 and 353: 350 Index Name Paper ref. Name Pape
- Page 354 and 355: 352 Index Name Paper ref. Name Pape
- Page 356 and 357: 354 Index Name Paper ref. Name Pape
- Page 358 and 359: 356 Index Name Paper ref. Name Pape
- Page 360 and 361: 358 Index Name Paper ref. Name Pape
- Page 362 and 363: 360 Index Name Paper ref. Name Pape
- Page 364 and 365: 362 Index Name Paper ref. Name Pape
- Page 366 and 367: 364 Index Name Paper ref. Name Pape
- Page 368 and 369: 366 Index Name Paper ref. Name Pape
- Page 370 and 371: 368 Index Name Paper ref. Name Pape
- Page 372 and 373: 370 Index Name Paper ref. Name Pape
- Page 376 and 377: 374 Index Name Paper ref. Name Pape
- Page 378 and 379: 376 Index Name Paper ref. Name Pape
- Page 380 and 381: 378 Index Name Paper ref. Name Pape
- Page 382 and 383: 380 Index Name Paper ref. Name Pape
- Page 384 and 385: 382 Notes Notes
- Page 386: Final Programme printed in Singapor